David Gandara, Co-Director of the Center for Experimental Therapeutics at the UC Davis Comprehensive Cancer Center, shared a post by Aakash Desai, Associate Director, Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, adding:
“Bravo Aakash Desai for this much needed study designed to optimize duration of dual IO therapy. But methods say non-inferiority trial. Cannot be with such a small sample size. correct? But exciting data that could be practice changing if duplicated in larger Phase III studies.”
Quoting Aakash Desai‘s post:
“DICIPLE: 4-year 6-month vs continuation Nivo+Ipi in mNSCLC PFS: 18.7m vs NR OS: 55.5m vs NR 18m OS: 80.6% vs 93.8% Grade 3-5 irAEs: 54% → 24% QoL: 15.5m vs NR (HR=0.36) at 6 months = same survival, less toxicity.”
Title: Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 “DICIPLE” Phase III trial
Authors: G Zalcman, A Madroszyk, E Guenzi, C Dayen, O Molinier, T Egenod, N Poté, D Debieuvre, S Beaucaire-Danel, A Dixmier, E Pichon, S Galland-Girodet, E Giroux-Leprieur, N Cloarec, J Cadranel, J Otto, P Romand, L Favier, S Martinez, C Mascaux, L Odier, A Cortot, C Audigier-Valette, A Langlais, E Amour, F Morin, M Antoine, V Gounant, V Westeel, A-C Toffart
Read the Full Article.
